EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Implementation of UGT1A1 genotype‐guided dosing of irinotecan in Europe

Niels Heersche, Erika Cecchin, Marzia Del Re, Vita Dolžan, Lana Ganoci, Mikko Niemi, Vincent Haufroid, Maarten J. Deenen, Jesse J. Swen, Markus Joerger, Paul J. Ross, Fabienne Thomas und 2 weitere

British Journal of Clinical Pharmacology · 19.11.2026

DOI: 10.1002/bcp.70942 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 19.11.2026. Verfasst von Niels Heersche und 13 weiteren Autor:innen. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Uridine diphosphate glucuronosyltransferase 1A1 ( UGT1A1 ) genotype‐guided dosing of irinotecan presents an individualized dosing strategy that improves patient safety while maintaining therapeutic efficacy. Nonetheless, little is known about its implementation across Europe. This survey‐based study provides an overview of UGT1A1 genotype‐guided irinotecan dosing practices across Europe and characterizes how institutional, regulatory and practical barriers affect its broader adoption.

Methods

A 41‐question survey assessing implementation, best practices and opinions related to UGT1A1 genotyping was distributed to healthcare professionals identified through professional societies and previous publications on pharmacogenetics or irinotecan, as well as through outreach to medical oncology departments and pharmacogenetic laboratories in Europe. The survey was open for participation for 10 weeks from January to March 2026.

Results

Of 345 healthcare professionals invited across 34 European countries, 119 (34%) from 107 centres in 27 countries participated. Respondents included clinicians ( N = 40), laboratory experts ( N = 34), pharmacologists ( N = 33) and researchers ( N = 12). Eighteen European countries reported varying extents of UGT1A1 genotyping for irinotecan treatment, with extensive pre‐treatment implementation currently present in Italy and the Netherlands. Eight countries reported no testing. The most frequently cited drivers of implementation were the presence of clinical guidelines, reimbursement and test availability. UGT1A1 genotyping panels differed considerably across laboratories.

Conclusions

While UGT1A1 genotype‐guided dosing of irinotecan is increasingly being adopted in Europe, broad and uniform implementation is still limited and thus far unevenly distributed. Achieving European implementation of pre‐treatment UGT1A1 genotyping for irinotecan will require the development and publication of clinical guidelines, test availability and coverage of genotyping costs.

Zitieren

APA

Heersche, N., Cecchin, E., Re, M. D., Dolžan, V., Ganoci, L., Niemi, M., Haufroid, V., Deenen, M. J., Swen, J. J., Joerger, M., Ross, P. J., Thomas, F., Schaik, R. H. N. V., & Mathijssen, R. H. J. (2026). Implementation of UGT1A1 genotype‐guided dosing of irinotecan in Europe. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70942

Vancouver

Heersche N, Cecchin E, Re MD, Dolžan V, Ganoci L, Niemi M, et al. Implementation of UGT1A1 genotype‐guided dosing of irinotecan in Europe. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70942

BibTeX
@article{Heersche2026,
  author = {Heersche, Niels and Cecchin, Erika and Re, Marzia Del and Dolžan, Vita and Ganoci, Lana and Niemi, Mikko and Haufroid, Vincent and Deenen, Maarten J. and Swen, Jesse J. and Joerger, Markus and Ross, Paul J. and Thomas, Fabienne and Schaik, Ron H. N. van and Mathijssen, Ron H. J.},
  title = {Implementation of UGT1A1 genotype‐guided dosing of irinotecan in Europe},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70942}
}
Kostenlos starten →